AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

So, exciting opportunities with EGFR and met ADCs [antibody drug conjugates] as well as EGFR and CD3 T-cell engagers in the ...

we are far from a consensus regarding the criteria for the use of anti-EGFR drugs. Unsatisfactory results in clinical trials invariably bring forth issues regarding lack of proper patient ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...